Ipilimumab Yervoy®
Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). The SHIKARI® Ipilimumab portfolio supports quantitative analysis of free ipilimumab and qualitative or quantitative detection of specific anti-ipilimumab antibodies in human serum or plasma.
Why Ipilimumab is relevant to biological-drug monitoring research
Ipilimumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Ipilimumab is a fully human IgG1 monoclonal antibody that binds CTLA-4 and blocks its inhibitory effect on T-cell activation. Source ↗
Approved Indications
EMA-authorised uses include defined treatment settings in melanoma, renal cell carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, MSI-H/dMMR colorectal cancer, squamous oesophageal cancer and hepatocellular carcinoma. EMA source ↗
Observed Week-7 Trough Exposure
A clinical study in advanced melanoma reported a wide distribution of week-7 trough concentrations under 3 mg/kg every three weeks:
Three verified Ipilimumab research assays
Ligand-binding, sandwich-principle ELISA for the quantitative analysis of free ipilimumab capable of binding CTLA-4 in human serum or plasma.
Sandwich-principle ELISA for quantitative determination of free anti-ipilimumab antibodies in human serum or plasma, with a confirmation workflow for positive samples.
Sandwich-principle screening ELISA for qualitative detection of binding anti-ipilimumab antibodies in human serum or plasma, reported as reactive or non-reactive according to assay-specific interpretation criteria.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Mode | Analyte | Sample | Volume | Run Time | Analytical Output / LOD | Tests | Shelf Life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-IPI | IPI-FD-YER | Quantitative | Free ipilimumab | Human serum / plasma | 10 µL | 70 min | LOD 3 ng/mL · LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATI quantitative | IPI-QNS-YER | Quantitative | Free antibodies to ipilimumab | Human serum / plasma | 20 µL | 140 min | LOD 6.25 ng/mL · LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATI qualitative | IPI-QLS-YER | Qualitative | Antibodies to ipilimumab | Human serum / plasma | 20 µL | 140 min | Reactive / non-reactive | 96 | 1 year | 2–8°C | 10–30°C |
Q-IPI has an LOD of 3 ng/mL and LOQ of 10 ng/mL. Quantitative S-ATI has an LOD of 6.25 ng/mL and LOQ of 10 ng/mL. Follow the link on each assay card for the current official product record on matriksbiotek.com.
Which assay fits your research question?
Choose the free-drug, quantitative antibody or qualitative antibody assay according to the analytical output required by the study.
Ipilimumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Ipilimumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.